Wayne Chu News Today

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -

- CX-904 initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC with Phase 1 initiation in EpCAM...

Operator: Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

FATE earnings call for the period ending October 31, 2021.

Operator Good day, ladies and gentlemen and welcome to the Fate Therapeutics First Quarter 2021 Financial Results Conference Call. This call is being webcast live on the Investors section of Fate Therapeutics website at fatetherapeutics.com. [Operator Instructions] I will now turn the call over to Scott Wolchko, President and CEO of Fate Therapeutics. Scott, you may begin. Scott Wolchko -- President And Chief Executive Officer Thank you. Good afternoon and thanks everyone for joining us for th...

Operator Welcome to the Fate Therapeutics Fourth Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section on Fates website at fatetherapeutics.com. As a reminder, todays call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics. The floor is yours. Scott Wolchko -- President and Chief Executive Officer Thank you. Good afternoon, a...